You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

140 search results for: symposium

AD and PN: Commonalities and Differences – A Case Study
expert video

AD and PN: Commonalities and Differences – A Case Study

Dermatology
Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.
View more
Type 2 Inflammation Alters the Structure and Function of the Skin in AD
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

Dermatology
Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.
View more
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Dermatology
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
View more
Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?
expert video

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?

Dermatology
Highlights from the ESPD 2023 ADVENT symposium, exploring burden, skin barrier normalization, and current treatments for pediatric atopic dermatitis.
View more
Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch
expert video

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Dermatology
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
View more
Skin Barrier Dysfunction in AD
expert video

Skin Barrier Dysfunction in AD

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.
View more
Dysbiosis, Skin Infections, and Itch
expert video

Dysbiosis, Skin Infections, and Itch

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.
View more
Disease Modification in AD
expert video

Disease Modification in AD

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Amy Paller discusses the benefits of early intervention for children with AD and the potential for disease modification.
View more
What is Early Intervention in AD?
expert video

What is Early Intervention in AD?

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Eulàlia Baselga, Dr. Amy Paller, and Dr. Lisa Weibel share their views on what “early” means when discussing early intervention in AD.
View more
Type 2 Inflammation Within Skin Tissue in AD
expert video

Type 2 Inflammation Within Skin Tissue in AD

Dermatology
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.
View more
Considerations for Disease Modification in AD
expert video

Considerations for Disease Modification in AD

Dermatology
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BelgiumChange country/region